178 related articles for article (PubMed ID: 26317020)
21. Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells.
Fattah OM; Cloutier SM; Kündig C; Felber LM; Gygi CM; Jichlinski P; Leisinger HJ; Gauthier ER; Mach JP; Deperthes D
Int J Cancer; 2006 Nov; 119(10):2455-63. PubMed ID: 16858684
[TBL] [Abstract][Full Text] [Related]
22. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
23. EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.
Agustoni F; Suda K; Yu H; Ren S; Rivard CJ; Ellison K; Caldwell C; Rozeboom L; Brovsky K; Hirsch FR
Cancer Treat Rev; 2019 Jan; 72():15-27. PubMed ID: 30445271
[TBL] [Abstract][Full Text] [Related]
24. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG
Crit Rev Oncol Hematol; 2001 Apr; 38(1):17-23. PubMed ID: 11255078
[TBL] [Abstract][Full Text] [Related]
25. Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas.
Gorgoulis V; Aninos D; Mikou P; Kanavaros P; Karameris A; Joardanoglou J; Rasidakis A; Veslemes M; Ozanne B; Spandidos DA
Anticancer Res; 1992; 12(4):1183-7. PubMed ID: 1503407
[TBL] [Abstract][Full Text] [Related]
26. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
Diaz Miqueli A; Blanco R; Garcia B; Badia T; Batista AE; Alonso R; Montero E
Hybridoma (Larchmt); 2007 Dec; 26(6):423-31. PubMed ID: 18158788
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.
Crombet T; Torres O; Rodríguez V; Menéndez A; Stevenson A; Ramos M; Torres F; Figueredo R; Veitía I; Iznaga N; Pérez R; Lage A
Hybridoma; 2001 Apr; 20(2):131-6. PubMed ID: 11394532
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
29. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
30. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
Mishra AK; Iznaga-Escobar N; Figueredo R; Jain VK; Dwarakanath BS; Pérez-Rodríguez R; Sharma RK; Mathew TL
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):653-60. PubMed ID: 12616957
[TBL] [Abstract][Full Text] [Related]
31. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
32. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
[TBL] [Abstract][Full Text] [Related]
33. [The growth inhibition of anti-EGF receptor monoclonal antibody to human lung adenocarcinoma cells].
Chen X; Zhang S; Bai C
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Apr; 21(4):233-5. PubMed ID: 11326972
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification.
Fernandez-Sánchez E; Ducongé J; Castillo R; Garcia I; Beausoleil I; Macías A
J Pharm Pharmacol; 2002 Jan; 54(1):59-64. PubMed ID: 11829130
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.
Modjtahedi H; Eccles SA; Box G; Styles J; Dean CJ
Cell Biophys; 1993; 22(1-3):129-46. PubMed ID: 7534211
[TBL] [Abstract][Full Text] [Related]
36. Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
Kaewjanthong P; Sooksai S; Sasano H; Hutvagner G; Bajan S; McGowan E; Boonyaratanakornkit V
PLoS One; 2022; 17(3):e0264717. PubMed ID: 35235599
[TBL] [Abstract][Full Text] [Related]
37. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma.
Morales-Morales A; Ducongé J; Caballero-Torres I; Núñez-Gandolff G; Fernández E; Iznaga-Escobar N
Nucl Med Biol; 1999 Apr; 26(3):275-9. PubMed ID: 10363798
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic heterogeneity in the NCI-H125 cell line affects biological activity using the epidermal growth factor receptor as target.
Blanco R; Cedeño M; González N; Rodríguez R; Sánchez J; Rengifo E
Acta Pharm; 2012 Dec; 62(4):581-91. PubMed ID: 23333890
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]